278 reports of this reaction
2.0% of all DESONIDE reports
#11 most reported adverse reaction
PSORIASIS is the #11 most commonly reported adverse reaction for DESONIDE, manufactured by Actavis Pharma, Inc.. There are 278 FDA adverse event reports linking DESONIDE to PSORIASIS. This represents approximately 2.0% of all 14,012 adverse event reports for this drug.
Patients taking DESONIDE who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for DESONIDE, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for DESONIDE:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 278 FDA reports for DESONIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 2.0% of all adverse event reports for DESONIDE, making it a notable side effect.
If you experience psoriasis while taking DESONIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.